EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of Circulating Tumor DNA and Carcinoembryonic Antigen Levels and Relationship with Clinicopathological Risk Factors and Prognostic Indices in Colorectal Cancer Patients

Şendağ YASLIKAYA, Mehmet TÜRKER, Yasemin AYDINALP CAMADAN, Mehmet Mutlu KIDI, Sedat BİTER, Esra ASARKAYA, Hatice ASOĞLU RÜZGAR, Şüheda ATAŞ İPEK, İ.Oğuz KARA, Berksoy ŞAHİN

Scientific Reports in Medicine · 2024

DOI: 10.37609/srinmed.20 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientific Reports in Medicine, 2024. Verfasst von Şendağ YASLIKAYA und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. ctDNA has emerged as a promising biomarker for CRC management, offering real-time insights into tumor burden and genetic mutations. This study investigates the correlation between CEA levels, ctDNA, clinicopathological factors, and treatment outcomes in early and advanced CRC patients.

Methods

The study retrospectively analyzed data from CRC patients, including early-stage disease and metastatic disease. ctDNA levels, demographic data, and clinical parameters such as CEA, inflammatory indexes, and tumor characteristics were evaluated to determine correlations with treatment outcomes.

Results

The study included 20 patients, with 60% diagnosed at the metastatic stage. The study found no statistically significant correlation between ctDNA levels and disease stage, recurrence, or overall survival. While CEA and ctDNA levels were measured, they did not demonstrate a significant relationship with treatment outcomes. Notably, ctDNA levels were higher in metastatic patients, though this was not statistically significant.

Conclusion

Despite its potential, the integration of ctDNA as a routine biomarker in CRC care faces challenges, including variability in measurement techniques and cost-effectiveness. However, ctDNA's ability to guide personalized treatment strategies and monitor disease recurrence holds promise. The study's findings align with previous research, suggesting ctDNA as a poor prognostic indicator, though further research is needed. ctDNA represents a significant advance in CRC management, offering non-invasive, real-time insights into tumor dynamics. Ongoing research is expected to solidify its role in personalized treatment planning, potentially leading to more effective and tailored therapies for CRC patients.

Zitieren

APA

YASLIKAYA, Ş., TÜRKER, M., CAMADAN, Y. A., KIDI, M. M., BİTER, S., ASARKAYA, E., RÜZGAR, H. A., İPEK, Ş. A., KARA, İ., & ŞAHİN, B. (2024). Evaluation of Circulating Tumor DNA and Carcinoembryonic Antigen Levels and Relationship with Clinicopathological Risk Factors and Prognostic Indices in Colorectal Cancer Patients. Scientific Reports in Medicine. https://doi.org/10.37609/srinmed.20

Vancouver

YASLIKAYA Ş, TÜRKER M, CAMADAN YA, KIDI MM, BİTER S, ASARKAYA E, et al. Evaluation of Circulating Tumor DNA and Carcinoembryonic Antigen Levels and Relationship with Clinicopathological Risk Factors and Prognostic Indices in Colorectal Cancer Patients. Scientific Reports in Medicine. 2024. doi:10.37609/srinmed.20

BibTeX
@article{YASLIKAYA2024,
  author = {YASLIKAYA, Şendağ and TÜRKER, Mehmet and CAMADAN, Yasemin AYDINALP and KIDI, Mehmet Mutlu and BİTER, Sedat and ASARKAYA, Esra and RÜZGAR, Hatice ASOĞLU and İPEK, Şüheda ATAŞ and KARA, İ.Oğuz and ŞAHİN, Berksoy},
  title = {Evaluation of Circulating Tumor DNA and Carcinoembryonic Antigen Levels and Relationship with Clinicopathological Risk Factors and Prognostic Indices in Colorectal Cancer Patients},
  journal = {Scientific Reports in Medicine},
  year = {2024},
  doi = {10.37609/srinmed.20}
}
Kostenlos starten →